scanX
Jubilant Pharmova

Jubilant Pharmova

1,042.90
-28.50
(-2.66%)
Market Cap
16,611.40 Cr
EPS
52.99
PE Ratio
34.22
Dividend Yield
0.48 %
Industry
Healthcare
52 Week High
1,309.90
52 Week Low
802.00
PB Ratio
2.66
Debt to Equity
0.55
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+75.00 %
+75.00 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
neutral
Jubilant Pharmova Appoints Arun Kumar Sharma as Interim CFO4 days ago
Jubilant Pharmova Limited appointed Arun Kumar Sharma as interim Chief Financial Officer and Key Managerial Personnel effective October 1, 2025. The Board of Directors approved the appointment on September 23, 2025, following recommendations from the Nomination, Remuneration and Compensation Committee and Audit Committee. The appointment is for an interim period to ensure smooth transition while the company continues its process to identify and appoint a permanent CFO. Sharma brings over three decades of experience in corporate finance, global treasury, investor relations, and risk management. He previously held CFO positions within the Jubilant Bhartia Group, including at Jubilant Pharma Holdings Inc. USA for approximately 4 years, Jubilant Lifesciences Limited for approximately 3 years, and Jubilant Pharmova Limited for approximately 2 years from April 2021 to May 2023.
positive
Jubilant Pharmova Completes USFDA Pharmacovigilance Inspection with Zero Observations7 days ago
Jubilant Pharmova Limited announced the completion of a United States Food and Drug Administration Post-marketing Adverse Drug Experience inspection of its subsidiary Jubilant Cadista Pharmaceuticals Inc, USA on September 19, 2025. The inspection concluded with no observations. The company stated this reaffirms their commitment to maintaining high standards of quality, safety, and compliance. Jubilant Cadista Pharmaceuticals is a subsidiary of Jubilant Pharma Limited, which is a wholly-owned subsidiary of Jubilant Pharmova Limited.
neutral
Jubilant Pharmova Schedules Virtual Investor Conference with Eight Investment FirmsAug 07, 2025
Jubilant Pharmova Limited has scheduled a virtual meeting with institutional investors on August 13, 2025, as part of the NBIE Virtual Investor Conference. The company will meet with representatives from eight investment firms, including ASK Investment Managers, Bajaj Finserv AMC, Parag Parikh Financial Advisory Services, Karma Capital, 2Point2 Capital, Bank Of India, Bay Capital, and Sundaram Alternates. The meeting is organized by Nirmal Bang Institutional Equities and includes a presentation to be discussed during the session. The company operates as a diversified pharmaceutical company with presence in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, drug discovery services, generics, and proprietary novel drugs. In quarterly results, the company reported revenue of Rs. 1,901 crores with EBITDA margins of 15.8%. The company has set Vision 2030 targets including doubling revenue from current levels, achieving 23-25% EBITDA margins, reaching zero net debt, and high teens return on capital employed.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,586.70
#1 3,80,702.50
33.18
#1 54,729.00
9.71
#1 10,980
-19.84
51.86
Divis Laboratories
5,689.50
1,51,038.30
65.50
9,712.00
18.67
2,191
26.74
36.39
Cipla
1,499.40
1,21,107.70
22.45
28,409.50
7.12
5,291
9.88
38.89
Torrent Pharmaceuticals
3,561.00
1,20,520.40
59.72
11,539.40
6.99
1,911
19.91
42.61
Dr Reddys Laboratories
1,253.10
1,04,580.10
#1 18.40
33,741.20
16.73
5,725
1.26
46.51
Mankind Pharma
2,482.90
1,02,476.40
54.18
12,744.20
#1 20.90
2,007
-18.14
44.66
Zydus Life Science
975.00
98,107.80
21.07
23,511.00
18.55
4,615
2.60
50.50
Lupin
1,919.80
87,676.40
23.72
22,909.50
13.74
3,306
#1 51.64
46.16
Alkem Laboratories
5,433.00
64,959.70
28.53
13,458.30
3.70
2,216
21.39
61.31
Aurobindo Pharma
1,090.00
63,307.40
18.84
32,345.60
9.43
3,484
-10.24
53.78
Forecast
Actual
Growth Rate
Revenue Growth
7.67 %
Net Income Growth
1,050.34 %
Cash Flow Change
10.38 %
ROE
900.75 %
ROCE
151.75 %
EBITDA Margin (Avg.)
17.88 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,529
1,430
1,439
1,327
1,466
1,405
1,365
1,444
1,576
1,545
1,628
2,045
2,247
2,056
2,249
2,382
2,346
2,163
2,249
1,544
1,563
1,175
1,631
1,838
1,614
1,617
1,638
1,304
1,513
1,452
1,598
1,543
1,682
1,575
1,686
1,714
1,764
2,130
1,764
1,823
1,928
1,891
Expenses
1,323
1,121
1,129
1,061
1,192
1,051
1,045
1,126
1,293
1,219
1,336
1,651
1,794
1,663
1,828
1,899
2,262
1,747
1,798
1,141
1,131
977
1,242
1,293
1,216
1,269
1,319
1,116
1,280
1,259
1,440
1,408
1,459
1,419
1,439
1,459
1,656
1,480
1,477
1,554
1,587
1,611
EBITDA
206
309
310
266
274
354
319
318
283
327
293
394
453
393
422
483
83
415
451
403
432
199
389
546
398
348
319
187
233
192
158
134
223
156
247
255
108
650
287
269
341
280
Operating Profit %
13 %
21 %
21 %
20 %
19 %
25 %
23 %
22 %
17 %
21 %
18 %
19 %
19 %
19 %
19 %
19 %
4 %
19 %
20 %
24 %
24 %
13 %
20 %
26 %
22 %
21 %
19 %
14 %
15 %
13 %
9 %
8 %
12 %
9 %
14 %
12 %
5 %
14 %
15 %
14 %
17 %
14 %
Depreciation
66
70
75
75
127
72
72
73
75
73
79
82
182
88
90
98
95
103
117
84
98
82
85
96
86
88
100
93
101
95
94
94
271
90
97
95
101
91
91
91
95
98
Interest
85
91
92
89
99
83
80
98
80
69
66
77
73
51
54
53
62
73
72
49
47
48
47
46
43
35
35
37
40
40
42
51
56
62
66
71
73
71
61
56
53
49
Profit Before Tax
68
168
161
145
69
218
193
166
160
203
168
261
227
286
302
356
-40
269
292
294
358
106
299
431
297
247
208
70
106
69
36
9
-86
25
98
101
-54
500
144
131
206
154
Tax
25
37
36
24
58
54
50
48
11
60
43
48
74
86
92
88
61
84
43
90
98
18
75
121
83
86
65
19
47
22
32
25
14
19
36
35
8
18
42
30
55
52
Net Profit
43
130
125
122
11
164
144
118
149
144
126
213
152
200
210
268
-101
185
249
203
261
88
224
310
214
161
143
51
59
47
5
-16
-101
6
62
66
-62
482
103
101
151
103
EPS in ₹
2.68
8.28
8.11
7.90
0.72
10.39
9.29
7.66
9.63
9.44
8.23
13.64
9.94
13.00
13.50
16.74
-6.38
11.61
15.66
12.77
16.35
5.53
14.06
19.46
13.43
10.09
8.97
3.20
3.74
2.96
0.34
-0.98
-6.15
0.40
3.94
4.22
-3.69
30.44
6.47
6.37
9.71
6.49
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
5,176
Current Assets
2,715
2,875
2,948
3,190
4,585
5,038
2,953
3,509
3,762
3,876
3,577
Capital Work in Progress
597
611
684
671
901
768
897
1,090
1,562
2,103
3,630
Investments
0
85
103
124
115
69
241
239
256
42
44
Other Assets
3,111
3,023
3,147
3,423
4,804
5,344
3,171
3,792
4,156
4,312
3,907
Total Liabilities
8,619
8,824
9,041
9,618
11,469
12,522
8,918
9,991
11,157
11,549
12,756
Current Liabilities
2,129
2,464
1,684
2,005
2,090
2,619
1,049
1,592
1,772
1,889
2,165
Non Current Liabilities
4,036
3,432
3,968
3,578
4,570
4,299
3,128
3,083
3,993
4,238
4,353
Total Equity
2,454
2,928
3,389
4,035
4,809
5,604
4,742
5,316
5,392
5,421
6,239
Reserve & Surplus
2,438
2,951
3,421
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
Share Capital
16
16
16
16
16
16
16
16
16
16
16
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-82
-52
117
-212
761
225
-652
482
30
-58
132
Investing Activities
-362
-309
-465
-614
-1,018
-267
-727
-323
-474
-596
513
Operating Activities
783
1,099
1,269
1,303
1,122
1,543
1,784
838
661
971
1,072
Financing Activities
-503
-843
-686
-901
657
-1,050
-1,709
-33
-157
-433
-1,453
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
50.68 %
47.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
23.21 %
0.00 %
19.06 %
19.49 %
17.94 %
16.96 %
17.22 %
17.40 %
DIIs
0.78 %
1.15 %
0.40 %
0.43 %
0.05 %
0.04 %
0.39 %
1.62 %
0.40 %
1.63 %
1.65 %
1.50 %
3.78 %
4.07 %
5.66 %
6.98 %
7.05 %
9.53 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.24 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.07 %
16.98 %
19.03 %
18.97 %
19.27 %
19.35 %
19.01 %
18.68 %
18.69 %
18.25 %
18.24 %
18.76 %
18.71 %
17.79 %
18.09 %
18.09 %
17.75 %
17.97 %
Others
32.47 %
31.19 %
29.89 %
29.92 %
30.00 %
29.93 %
29.92 %
29.02 %
28.98 %
29.44 %
6.22 %
29.06 %
7.77 %
7.97 %
7.63 %
7.30 %
7.31 %
7.42 %
No of Share Holders
0
61,942
87,493
1,13,776
1,09,420
1,08,063
1,09,410
1,05,632
97,935
93,375
89,376
86,588
92,264
81,992
89,456
1,02,442
96,526
99,673

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 3 4.5 5 5 5 5 5 5
Dividend Yield (%) 0.00 0.36 0.45 1.81 0.73 1.29 1.79 0.88 0.56 0.48

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
01 Feb 2021 CHANGE OF NAME Change Of Name
NA
 01 Feb 2021 886.60 886.60
06 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
 05 Aug 2021 843.05 657.45
12 Aug 2022 DIVIDEND Dividend
₹ 5.00 /share
 11 Aug 2022 397.10 353.35
10 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
 10 Aug 2023 362.90 404.75
02 Aug 2024 DIVIDEND Dividend
₹ 5.00 /share
 02 Aug 2024 703.90 866.20
30 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Aug 2024 849.00 920.60
25 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Oct 2024 1,228.25 1,108.05
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 31 Jan 2025 937.70 954.95
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 16 May 2025 896.35 905.60
25 Jul 2025 DIVIDEND Dividend
₹ 5.00 /share
 25 Jul 2025 905.60 1,175.00
29 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 29 Jul 2025 1,210.30 1,174.20
29 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 29 Aug 2025 1,119.10 1,039.30

Announcements

Announcement under Regulation 30 (LODR)-Change in Management4 days ago
Board Meeting Outcome for Outcome Of Board Meeting Held On September 23 20254 days ago
Disclosure Under Regulation 30 - Jubilant Pharmova Announces Completion Of Pharmacovigilance Inspection By The USFDA With No Observations7 days ago
Reminder Email Sent To Shareholders Intimating About The 100 Days CampaignSep 12, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Orders Passed By The Additional Commissioner Central Tax (Appeals) MysuruSep 02, 2025
Disclosure Under Regulation 30 - Completion Of Sale And Transfer Of API BusinessSep 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 01, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorSep 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 29, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 29, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Aug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Intimation Regarding A Letter Dispatched To The Shareholders For Annual Report Of The Company For FY 2024-25Aug 05, 2025
Reg. 34 (1) Annual Report.Aug 05, 2025
Notice Of 47Th Annual General Meeting Alongwith The Annual Report For The Financial Year 2024-25Aug 05, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 05, 2025
E-Mail Communication To Shareholders Intimating About Deduction Of Tax At Source (TDS) On Final Dividend For FY 2024-25Aug 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Completion Of Pre-Approval Inspection (PAI) By USFDA Of Solid Dosage Manufacturing Facility At Roorkee IndiaAug 02, 2025
Submission Of Communication Sent To Shareholders Relating To Notice Of Transfer Of Equity Shares / Dividend To Investor Education And Protection Fund AuthorityAug 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 30, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJul 29, 2025
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Jul 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 29, 2025
Grant Of Stock OptionsJul 29, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 29, 2025
Unaudited Results For The Quarter Ended June 30 2025Jul 29, 2025
Board Meeting Outcome for Approval Of Unaudited Financial ResultsJul 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 24, 2025
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025Jul 23, 2025
Disclosure Under Regulation 30Jul 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 25, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 16, 2025
Board Meeting Outcome for Outcome Of Board MeetingJun 12, 2025
Announcement under Regulation 30 (LODR)-RestructuringJun 12, 2025
Intimation Under Regulation 30 - Receipt Of Rectification Order From The Income Tax DepartmentJun 11, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 04, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 16, 2025
The Company Has Informed The Exchange That Record Date For The Purpose Of Dividend Is July 25 2025.May 16, 2025

Technical Indicators

RSI(14)
Neutral
34.40
ATR(14)
Volatile
32.76
STOCH(9,6)
Oversold
18.04
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-4.47
ADX(14)
Weak Trend
20.52
UO(9)
Bearish
49.44
ROC(12)
Downtrend And Accelerating
-8.49
WillR(14)
Oversold
-80.06
Bearish
3
Neutral
4
Bullish
2

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Focused Fund Direct-Growth
3.19%
123437
0.32%
3.19%
Bandhan Small Cap Fund Direct-Growth
1.08%
109089
-0.13%
-0.15%
Bajaj Finserv Small Cap Fund Direct-Growth
0.00%
-47361
-0.47%
0.00%
Aditya Birla Sun Life Bal Bhavishya Yojna Direct-Growth
0.83%
45083
0.36%
0.83%
Kotak Contra Fund Direct-Growth
1.32%
39763
-0.12%
-0.13%
HDFC Pharma And Healthcare Fund Direct - Growth
1.70%
37500
-0.03%
-0.05%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
1.15%
14014
0.04%
1.15%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.41%
3588
0.41%
0.41%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.41%
2757
-0.05%
-0.04%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.41%
1222
-0.05%
-0.04%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.41%
1084
-0.05%
-0.04%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.41%
840
-0.05%
-0.04%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.41%
659
-0.05%
-0.04%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.41%
438
-0.05%
-0.04%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.18%
-247
-0.02%
-0.02%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.04%
187
-0.01%
-0.01%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.41%
135
-0.06%
-0.04%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.41%
118
-0.05%
-0.04%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.41%
71
-0.05%
-0.04%
Axis Nifty 500 Index Fund Direct-Growth
0.04%
61
-0.01%
-0.01%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.10%
-50
-0.02%
-0.01%
Groww Nifty Total Market Index Fund Direct - Growth
0.04%
28
-0.01%
-0.01%
SBI Nifty 500 Index Fund Direct-Growth
0.04%
16
-0.01%
-0.01%
ICICI Prudential Nifty 500 Index Fund Direct-Growth
0.04%
13
-0.01%
-0.01%
Angel One Nifty Total Market Index Fund Direct - Growth
0.04%
12
-0.01%
0.00%

About Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and Allergy Therapy Products. It has 6 US FDA approved manufacturing facilities in India, USA and Canada, and a network of over 48 radiopharmacies in the USA. Jubilant Pharmova provides drug discovery and development services, and is working on addressing unmet medical needs in oncology and autoimmune diseases. The company has filed numerous Drug Master Files in various countries and has expanded its manufacturing and research capabilities in recent years.
Website
https://www.jubl.com
Chairperson NameShyam S Bhartia
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Candlestick Screeners
Technical Screeners
Price & Volume Screeners
Fundamental Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104